Related references
Note: Only part of the references are listed.Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial
Emanuele Angelucci et al.
ANNALS OF INTERNAL MEDICINE (2020)
ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications
Peter Valent
PATHOBIOLOGY (2019)
Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes
Carolien Duetz et al.
PATHOBIOLOGY (2019)
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
Daniel A. Pollyea et al.
LEUKEMIA (2019)
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
Michael R. Savona et al.
LANCET HAEMATOLOGY (2019)
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Guillermo Garcia-Manero et al.
LANCET HAEMATOLOGY (2019)
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
U. Platzbecker et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Detlef Haase et al.
LEUKEMIA (2019)
Azacitidine in Lower-Risk Myelodysplastic Syndromes: AMeta-Analysis of Data from Prospective Studies
Rami Komrokji et al.
ONCOLOGIST (2018)
Azacitidine in the real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada
Lee Mozessohn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Pierre Fenaux et al.
LEUKEMIA (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Good news for patients with myelodysplastic syndromes and thrombocytopenia
Moshe Mittelman
LANCET HAEMATOLOGY (2018)
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
Yasushi Miyazaki et al.
LEUKEMIA RESEARCH (2018)
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl et al.
BLOOD ADVANCES (2018)
Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies
Michael W. Drazer et al.
BLOOD ADVANCES (2018)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
Peter Valent et al.
ONCOTARGET (2017)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
Cytogenetic Clonal Evolution in Myelodysplastic Syndromes Is Associated With Inferior Prognosis
Judith Neukirchen et al.
CANCER (2017)
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati et al.
BLOOD (2017)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Theo de Witte et al.
BLOOD (2017)
Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation
N. Jaekel et al.
BONE MARROW TRANSPLANTATION (2016)
The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system
C. Alhan et al.
LEUKEMIA (2016)
Causes of death in 2877 patients with myelodysplastic syndromes
Kathrin Nachtkamp et al.
ANNALS OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Sylvain Thepot et al.
HAEMATOLOGICA (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Sylvain Thepot et al.
HAEMATOLOGICA (2016)
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance
Brian Kwok et al.
BLOOD (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
The inflammatory microenvironment in MDS
Lili Yang et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes
Jennifer Schemenau et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie et al.
NATURE MEDICINE (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Valeria Santini et al.
BLOOD (2013)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Transplantation for myelodysplastic syndromes 2013
Jennifer E. Vaughn et al.
CURRENT OPINION IN HEMATOLOGY (2013)
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
Steven D. Gore et al.
HAEMATOLOGICA (2013)
Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database
Maria Teresa Voso et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data
Ronald Brand et al.
PLOS ONE (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Lenalidomide for Treatment of Myelodysplastic Syndromes
Rami S. Komrokji et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma
Jing Shen et al.
EPIGENETICS (2012)
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
T. M. Westers et al.
LEUKEMIA (2012)
Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Dusseldorf MDS registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2012)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes
Noemi B. A. Roy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Therapy-related myeloid neoplasms
Giuseppe Leone et al.
CURRENT OPINION IN ONCOLOGY (2011)
EFFICACY AND SAFETY OF ADMINISTRATION OF ORAL IRON CHELATOR DEFERIPRONE IN PATIENTS WITH EARLY MYELODYSPLASTIC SYNDROME
Jaroslav Cermak et al.
HEMOGLOBIN (2011)
Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Risk of Myelodysplastic Syndromes in People Exposed to Ionizing Radiation: A Retrospective Cohort Study of Nagasaki Atomic Bomb Survivors
Masako Iwanaga et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence and prevalence of myelodysplastic syndromes: Data from the Dusseldorf MDS-registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Cause of Death in Patients With Lower-Risk Myelodysplastic Syndrome
Farshid Dayyani et al.
CANCER (2010)
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis
Ronit Gurion et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
Norbert Gattermann et al.
LEUKEMIA RESEARCH (2010)
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Ying Jiang et al.
BLOOD (2009)
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L. Greenberg et al.
BLOOD (2009)
Impact of iron overload in myelodysplastic syndromes
Pierre Fenaux et al.
BLOOD REVIEWS (2009)
Cardiac T2*Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major
P. Kirk et al.
CIRCULATION (2009)
Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions
P. Valent et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2009)
Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes
Matteo Giovanni Della Porta et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)
Uwe Platzbecker et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF:: the GFM experience
Sophie Park et al.
BLOOD (2008)
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
Elaine M. Sloand et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era;: the GFM experience with EPO and thalidomide
C. Kelaidi et al.
LEUKEMIA RESEARCH (2008)
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes
G. Buesche et al.
LEUKEMIA (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:: evidence from a core dataset of 2124 patients
Detlef Haase et al.
BLOOD (2007)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes
Sabine Knipp et al.
CANCER (2007)
Gene silencing by DNA methylation in haematological malignancies
Jacqueline Boultwood et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
Z. Y. Lim et al.
LEUKEMIA (2007)
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
Philippe Armand et al.
BLOOD (2007)
Proposals for standardized Protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes
Claudia Haferlach et al.
GENES CHROMOSOMES & CANCER (2007)
Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes
Ali-Reza Golshayan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome - Comparison with historical experience
Hagop M. Kantarjian et al.
CANCER (2007)
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
Peter Valent et al.
LEUKEMIA RESEARCH (2007)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making
L Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Risk of cancer after low doses of ionising radiation - retrospective cohort study in 15 countries
E Cardis et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
BA Davis et al.
BLOOD (2004)
A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
Y Saunthararajah et al.
BLOOD (2003)
Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool
PD Jensen et al.
BLOOD (2003)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
E Hellström-Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
J Crawford et al.
CANCER (2002)
Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
EH Estey et al.
BLOOD (2001)
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
CA Dykewicz
CLINICAL INFECTIOUS DISEASES (2001)
Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases
E Bourgeois et al.
LEUKEMIA (2001)
Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France
C Nisse et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
